The Eye Health Stack: Lutein, Zeaxanthin, Astaxanthin, and Omega-3

← Back to articles

The AREDS and AREDS2 trials remain among the cleanest supplement trials in medicine. Their conclusion: a specific combination of lutein, zeaxanthin, vitamin C, vitamin E, zinc, and copper modestly slows progression from intermediate to advanced age-related macular degeneration (AMD). Outside the AREDS formula, astaxanthin and omega-3 have additional trial evidence for adjacent eye-health endpoints (accommodative fatigue, dry eye).

Layer 1: Lutein + Zeaxanthin, 10 + 2 mg Daily

The macular pigment carotenoids that filter blue light and quench reactive oxygen species in the retina. AREDS2 confirmed these as the preferred formula replacement for beta-carotene (which AREDS used originally but increases lung cancer risk in smokers). The 10 + 2 mg ratio mirrors the dietary lutein:zeaxanthin ratio that confers maximum macular pigment optical density gains. See lutein/zeaxanthin piece.

Layer 2: Vitamin C + Vitamin E + Zinc + Copper (AREDS2 Doses)

Vitamin C 500 mg + vitamin E 400 IU + zinc oxide 25 mg + cupric oxide 2 mg complete the AREDS2 formula. Together these reduced progression to advanced AMD by ~25% over 5 years in adults with intermediate AMD or advanced AMD in one eye. The full formula matters — individual components alone have much smaller signals. See AMD condition piece.

Layer 3: Astaxanthin, 4–12 mg Daily — Accommodative/Digital Eye Strain

Astaxanthin (the carotenoid that gives salmon its pink color) has positive trial signals in accommodative fatigue, reduced eye strain from prolonged screen use, and modest signals in dry eye symptom reduction. Japanese RCTs at 6-12 mg daily show improvements in accommodative reserve and asthenopia symptoms. See astaxanthin piece.

Layer 4: EPA-Dominant Omega-3, 1.5–2 g Daily — Dry Eye Component

The DREAM trial was null on the primary symptom endpoint for high-dose fish oil in moderate-severe dry eye, but smaller earlier trials and the 2019 Cochrane review concluded omega-3 produces modest improvements in tear breakup time and Schirmer scores. Useful in adults with dry-eye-dominant complaints. Don't expect dramatic effects. See dry eye protocol.

Layer 5 (Optional): Bilberry Extract, 160 mg Daily — Mostly Observational

Bilberry has observational data for night vision and capillary fragility, but RCT evidence is thin. Reasonable optional adjunct but not a primary component. See bilberry piece.

What NOT to Take

Avoid beta-carotene supplementation, particularly in smokers — CARET and ATBC trials showed increased lung cancer risk. AREDS2 specifically removed it. Skip "eye health megavitamin" formulas that exceed AREDS doses by 5× — no incremental benefit, and the cardiovascular and oncologic risks rise. Avoid lycopene as a primary AMD intervention — null trial data. Skip bilberry-only products marketed for AMD — observational data only.

How to Run the Stack

Annual ophthalmologic exam from age 60. Smoking cessation is the single largest preventive intervention. Mediterranean-pattern diet (leafy greens, fish, olive oil) provides the AREDS components from food. Supplement the AREDS2 formula (lutein 10 + zeaxanthin 2 + C 500 + E 400 + zinc 25 + copper 2 mg daily) for adults with intermediate AMD on retinal exam. Add astaxanthin for screen-related eye strain. Omega-3 for dry eye comorbidity. See related cataract prevention.